5 Key Takeaways

• 1

  Piers Ingram cited the first dual-payload antibody-drug conjugate developed by Hummingbird Bioscience with Callio Therapeutics entering clinical testing as a professional highlight.

• 2

  Ingram said immunology is making underrecognized progress through engineered approaches combining immuno-oncology, antibody-drug conjugates, and T-cell engagers.

• 3

  Ingram identified clinical execution as drug development’s main bottleneck and said better trial execution and use of study data could accelerate innovation.

• 4

  Ingram advocated treating drug discovery as an engineering challenge, using design principles, iterative feedback, and data to improve molecule discovery and optimization.

• 5

  Ingram expects artificial intelligence, computational biology, and advanced laboratory models to reduce reliance on animal models and better reflect human biology.